iSpecimen Inc (ISPC) - Net Assets
Based on the latest financial reports, iSpecimen Inc (ISPC) has net assets worth $3.09 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.53 Million) and total liabilities ($6.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check iSpecimen Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.09 Million |
| % of Total Assets | 32.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | -89.63% |
| 10-Year Change | N/A |
| Growth Volatility | 22.32 |
iSpecimen Inc - Net Assets Trend (2018–2025)
This chart illustrates how iSpecimen Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of iSpecimen Inc for the complete picture of this company's asset base.
Annual Net Assets for iSpecimen Inc (2018–2025)
The table below shows the annual net assets of iSpecimen Inc from 2018 to 2025. For live valuation and market cap data, see iSpecimen Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.09 Million | -6.73% |
| 2024-12-31 | $3.31 Million | -66.01% |
| 2023-12-31 | $9.74 Million | -52.04% |
| 2022-12-31 | $20.31 Million | -31.83% |
| 2021-12-31 | $29.79 Million | +209.21% |
| 2020-12-31 | $-27.28 Million | -20.07% |
| 2019-12-31 | $-22.72 Million | -23.31% |
| 2018-12-31 | $-18.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to iSpecimen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6260369600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $848.00 | 0.03% |
| Other Components | $85.44 Million | 2766.55% |
| Total Equity | $3.09 Million | 100.00% |
iSpecimen Inc Competitors by Market Cap
The table below lists competitors of iSpecimen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
KD Corporation
KQ:044180
|
$3.86 Million |
|
Property Franchise Group PLC
LSE:TPFG
|
$3.86 Million |
|
Shuttle Pharmaceuticals Inc
NASDAQ:SHPH
|
$3.87 Million |
|
Marston’s PLC
LSE:MARS
|
$3.87 Million |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
$3.86 Million |
|
Voxtur Analytics Corp
V:VXTR
|
$3.86 Million |
|
Tiphone Mobile Indonesia Tbk
JK:TELE
|
$3.86 Million |
|
Avrupa Minerals Ltd
V:AVU
|
$3.85 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iSpecimen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,311,008 to 3,088,231, a change of -222,777 (-6.7%).
- Net loss of 10,487,532 reduced equity.
- New share issuances of 11,249,572 increased equity.
- Other factors decreased equity by 984,817.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.49 Million | -339.6% |
| Share Issuances | $11.25 Million | +364.27% |
| Other Changes | $-984.82K | -31.89% |
| Total Change | $- | -6.73% |
Book Value vs Market Value Analysis
This analysis compares iSpecimen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-393.19 | $5.62 | x |
| 2019-12-31 | $-485.39 | $5.62 | x |
| 2020-12-31 | $-582.73 | $5.62 | x |
| 2021-12-31 | $72.91 | $5.62 | x |
| 2022-12-31 | $45.93 | $5.62 | x |
| 2023-12-31 | $21.55 | $5.62 | x |
| 2024-12-31 | $4.66 | $5.62 | x |
| 2025-12-31 | $0.67 | $5.62 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iSpecimen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -339.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -543.68%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 3.09x
- Recent ROE (-339.60%) is below the historical average (-113.94%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -121.67% | 1.09x | 0.00x | $-3.50 Million |
| 2019 | 0.00% | -109.97% | 1.02x | 0.00x | $-2.46 Million |
| 2020 | 0.00% | -56.84% | 1.32x | 0.00x | $-1.92 Million |
| 2021 | -30.08% | -80.48% | 0.31x | 1.20x | $-11.94 Million |
| 2022 | -50.45% | -98.50% | 0.42x | 1.21x | $-12.28 Million |
| 2023 | -113.95% | -111.80% | 0.63x | 1.62x | $-12.07 Million |
| 2024 | -377.46% | -134.51% | 0.99x | 2.82x | $-12.83 Million |
| 2025 | -339.60% | -543.68% | 0.20x | 3.09x | $-10.80 Million |
Industry Comparison
This section compares iSpecimen Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $543,908,184
- Average return on equity (ROE) among peers: -221.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iSpecimen Inc (ISPC) | $3.09 Million | 0.00% | 2.09x | $3.86 Million |
| Agilent Technologies Inc (A) | $2.51 Billion | -1.24% | 2.04x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $11.11 Million | -144.24% | 0.30x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $9.85 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $154.44 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About iSpecimen Inc
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecim… Read more